- Mission [1]
- FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science
and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities
to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency
preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical
products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence
and accountability. The Nonprescription Drugs Advisory Committee supports FDA's strategic priorities by reviewing and evaluating
available data concerning the safety and effectiveness of over-the-counter (nonprescription) human drug products, or any other
FDA-regulated product, for use in the treatment of a broad spectrum of human symptoms and diseases and advises the Commissioner
of Food and Drugs either on the promulgation of monographs establishing conditions under which these drugs are generally recognized
as safe and effective and not misbranded or on the approval of new drug applications for such drugs. The Committee will serve
as a forum for the exchange of views regarding the prescription and nonprescription status, including switches from one status
to another, of these various drug products and combinations thereof. The Committee may also conduct peer review of agency
sponsored intramural and extramural scientific biomedical programs in support of FDA’s mission and regulatory responsibilities.
This support the development of safe and effective new medical technologies, and advances the status of the Agency as a science-based
and science-led regulatory agency, providing global leadership in the protection of public health.
|
